In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.42 below Vaxcyte Inc average.

Within Biotechnology & Pharmaceuticals industry 119 other companies have achieved higher Quick Ratio than Vaxcyte Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 230 to 2340.

Explain Quick Ratio?
How much Cash & cash equivalents PCVX�s has?
What are PCVX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PCVX/financial-strength

https://api.csimarket.com/api/v1/companies/PCVX/fundamentals

https://api.csimarket.com/api/v1/companies/PCVX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

PCVX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	227.4 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-92.67 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.42	Subscribe	Subscribe	Subscribe	Subscribe
PCVX's Total Ranking	# 2340	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	9 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-31.51 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 120
Healthcare Sector	# 700
Overall Market	# 2340

Quick Ratio Statistics
High	Average	Low
62.04	20.88	0.68
(Jun 30 2020)		(Jun 30 2026)

Financial Statements
Vaxcyte Inc 's Current Liabilities	$ 296 Millions	Visit PCVX's Balance sheet
Vaxcyte Inc 's Cash & cash equivalent	$ 125 Millions	Visit PCVX's Balance sheet
Source of PCVX's Sales		Visit PCVX's Sales by Geography

Cumulative Vaxcyte Inc 's Quick Ratio

PCVX's Quick Ratio for the trailling 12 Months

PCVX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	160.4 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-33.66 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	4.55	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3958	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	34.94 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-30.54 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to PCVX Financial Strength Comparisons >> Go to Compare PCVX Quick Ratio to its Competitors

News about Vaxcyte Inc Quick Ratio

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Vaxcyte, Inc., a clinical-stage vaccine innovation company specializing in high-fidelity vaccines against bacterial diseases, has recently announced the initiation of an underwritten public offering of its common stock and pre-funded warrants. With a mission to safeguard humanity from the consequences of bacterial diseases, Vaxcyte aims to raise capital through this offering to further fuel its groundbreaking research and development efforts.
The company plans to offer all shares of common stock and pre-funded warrants in this public offering. In addition, Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total shares of common stock offered, including those underlying the pre-funded warrants. However, the completion, size, and terms of the offering are subject to market conditions and other variables, and therefore, are not guaranteed.

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $295.70 millions, cumulative Quick Ratio decreased to 4.55 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Vaxcyte Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3536 to 3958.

Explain Quick Ratio?
How much Cash & cash equivalents PCVX�s has?
What are PCVX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 142
Healthcare Sector	# 893
Within the Market	# 3958

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.29	5.71	0.98
(Dec 31 2022)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Amgen Inc	1.11	$ 25,811.000 Millions	$ 23,231.000 Millions
Sab Biotherapeutics Inc	0.98	$ 14.438 Millions	$ 14.798 Millions
Bio techne Corp	0.97	$ 350.036 Millions	$ 361.269 Millions
C4 Therapeutics Inc	0.81	$ 33.492 Millions	$ 41.460 Millions
Allogene Therapeutics Inc	0.76	$ 29.270 Millions	$ 38.498 Millions
Ocugen Inc	0.71	$ 84.257 Millions	$ 118.901 Millions
Neurocrine Biosciences Inc	0.59	$ 739.100 Millions	$ 1,242.800 Millions
Iovance Biotherapeutics inc	0.55	$ 57.934 Millions	$ 105.774 Millions
Agenus Inc	0.43	$ 86.936 Millions	$ 203.691 Millions
Vaxcyte Inc	0.42	$ 125.470 Millions	$ 295.697 Millions
Vaxart Inc	0.41	$ 30.435 Millions	$ 73.934 Millions
Surrozen Inc	0.35	$ 100.353 Millions	$ 286.684 Millions
Biogen Inc	0.16	$ 628.100 Millions	$ 3,898.400 Millions

Date modified: 2026-11-05T05:58:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.